Usefulness of echocardiography to detect cardiac involvement in COVID-19 patients

Matteo Cameli MD, PhD | Maria Concetta Pastore MD | Hatem Soliman Aboumarie MD | Giulia Elena Mandoli MD
Flavio D’Ascenzi MD, PhD | Paolo Cameli MD | Elisa Bigio MD
Federico Franchi MD | Sergio Mondillo MD | Serafina Valente MD

1 Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Siena, Italy
2 Adult Intensive Care Unit, Royal Brompton and Harefield NHS Foundation Trust, London, UK
3 Department of Clinical Medical and Neurosciences, Respiratory Disease and Lung Transplantation Section, Le Scotte Hospital, University of Siena, Siena, Italy
4 Anesthesiology Unit, Alta Val D’Elsa Hospital, Siena, Italy
5 Department of Medical Biotechnologies, Anesthesia and Intensive Care, University of Siena, Siena, Italy

Correspondence
Maria Concetta Pastore, MD, Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Viale Bracci 1, Siena, Italy.
Email: pastore2411@gmail.com

Abstract
Coronavirus disease 2019 (COVID-19) outbreak is a current global healthcare burden, leading to the life-threatening severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, evidence showed that, even if the prevalence of COVID-19 damage consists in pulmonary lesions and symptoms, it could also affect other organs, such as heart, liver, and spleen. Particularly, some infected patients refer to the emergency department for cardiovascular symptoms, and around 10% of COVID-19 victims had finally developed heart injury. Therefore, the use of echocardiography, according to the safety local protocols and ensuring the use of personal protective equipment, could be useful firstly to discriminate between primary cardiac disease or COVID-19–related myocardial damage, and then for assessing and monitoring COVID-19 cardiovascular complications: acute myocarditis and arrhythmias, acute heart failure, sepsis-induced myocardial impairment, and right ventricular failure derived from treatment with high-pressure mechanical ventilation. The present review aims to enlighten the applications of transthoracic echocardiography for the diagnostic and therapeutic management of myocardial damage in COVID-19 patients.

Keywords
heart failure, COVID-19, echocardiography, myocardial injury, myocarditis, SARS-CoV2

1 | INTRODUCTION

Coronavirus disease 2019 (COVID-19) pandemic is currently affecting 212 countries throughout the world, with high morbidity and mortality rates. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection could be easily transmitted through human-to-human contact or respiratory droplets, and individuals with underlying cardiovascular disease are at highest risk for severe disease and death, reaching 10.5% fatality rate. Even though the clinical manifestations of COVID-19 are dominated by respiratory symptoms, some infected patient initially presents typical cardiovascular symptoms (ie, chest discomfort, palpitations, dyspnea). In these cases, it could be challenging for the clinician to establish whether symptoms represent the first expression of SARS-CoV-2 cardiac involvement, or they derive from a primary cardiac pathologic condition. Moreover, several cases of COVID-19–induced myocardial damage has been observed, particularly in critical subjects (in China, 11.8% of dead subjects without underlying cardiovascular disease had myocardial injury), consisting in acute myocardial injury and myocarditis, cardiac arrest, heart failure (HF) due to pulmonary hypertension (PH), or shock states. This is probably due to coronavirus-related damage which also involves heart and other organs, provoking degeneration and necrosis of parenchymal cells and formation of hyaline thrombus in small vessels, as shown in a
postmortem examination of 3 COVID-19 victims. In two studies by Shi et al. and Guo et al., among 460 and 187 patients hospitalized for COVID-19, respectively, 20% and 28% had acute myocardial injury, which was associated with higher mortality and incidence of complications, such as acute respiratory distress syndrome (ARDS), malignant arrhythmias, acute renal injury, and coagulopathy. Echocardiography is considered the first-choice diagnostic technique for the evaluation of myocardial structure and function, due to its high availability and cost-effectiveness. For this reason, a conscious inhospital application of transthoracic echocardiography (TTE), using a focused and safe approach, according to the latest European Association of Cardiovascular Imaging (EACVI) and American Society of Echocardiography (ASE) recommendations, could reduce the potential risks of COVID-19 heart injury, providing early detection and treatment. These documents do not provide strict indications on whether to perform or reject an echocardiographic examination in this period of social distancing, since it should be tailored on the single patient, trying to avoid unnecessary examinations. However, American College of Cardiology (ACC) Clinical Guidance for COVID-19 suggests that patients demonstrating HF, arrhythmia, electrocardiographic (ECG) changes, or cardiomegaly should undergo echocardiography. Moreover, the evaluation of the right ventricle (RV) could be important in ventilated patients for the early assessment of high positive end-expiratory pressures (PEEP)-induced cardiopulmonary overload and in patients with suspected acute cor pulmonale.

The present review discusses the different clinical inhospital applications of echocardiography, from emergency department to COVID wards and ICU, to highlight its usefulness for assisting clinicians in the daily diagnostic and therapeutic management of COVID-19-affected patients.

2 | SUSPECTED ACUTE CORONARY SYNDROMES

As reported by the National Health Commission of China (NHC), some of the confirmed cases of SARS-CoV-2 patients first showed cardiovascular rather than respiratory symptoms. After the nasal or pharyngeal swab has done to test COVID-19 patients' status before the admission, the first step of triaging usually comprises ECG and blood cardiac enzymes dosage; however, evidence has shown that troponin and brain natriuretic peptide (BNP) levels could increase due to COVID-19 itself, proportionally to the severity of the disease. In fact, a meta-analysis showed that troponin I values were significantly higher in patients with severe compared to those with mild illness due to SARS-CoV-2 infection. He et al conducted a study in critical COVID-19 patients dividing them into two groups according to the presence (24 patients, 44.4%) or absence (30 patients, 55.6%) of myocardial injury, revealing that the injury group presented significantly higher inhospital mortality (75.0% vs. 26.7% [8/30], \( P = .001 \)), C-reactive protein (CRP), and N-terminal pro-BNP (NT-pro-BNP, \( P < .01 \)).

Chen et al also analyzed 150 COVID-19 subjects and found 22 of them (14.7%) having troponin elevation, which was independently correlated with COVID-19 critical severity with multivariate regression analysis (odds ratio, OR = 26.909, 95% CI 4.086-177.226, \( P = .001 \)). Accordingly, ACC COVID-19 clinical guidance pointed out that that classic symptoms and presentation of acute myocardial infarction may be unclear in the context of COVID-19, resulting in underdiagnosis. Moreover, in a small Italian report of 28 COVID-19 patients with ST-elevation myocardial infarction (STEMI), 78.6% of them presented with acute chest pain, while 82.1% had regional wall-motion abnormalities at TTE.

In fact, echocardiography could support diagnosis in this setting, revealing suggestive signs of acute myocardial infarction, new-onset or worsening congestive HF, pericardial effusion or tamponade, and RV overload due to pulmonary embolism or cor pulmonale (Table 1). This would lead to an accurate triaging, ensuring each patient the appropriate treatment.

3 | ACUTE MYOCARDITIS AND ARRHYTHMIAS

Various degrees of myocardial injury (defined as raised troponin levels over the 99th percentile of reference range) have been recently shown in patients with COVID-19. In a clinical study involving 138 patients with COVID-19, 10 patients (7.2%) had acute myocardial injury and 23 (16.7%) had arrhythmia, the majority of them during hospitalization in intensive care unit (ICU). There are many possible causes of acute myocardial injury in critically ill patients, including acute coronary syndrome, HF, myocarditis, hypotension or shock, sepsis, and infection. To date, the mechanism responsible of myocardial injury in COVID-19 is uncertain; however, hypothesis has focused on local or systemic immune response, possibly causing cardiomyocytes degeneration and/or microvascular thrombosis.

Accordingly, current reports suggest that the majority of COVID-19 patients with myocardial injury without evidence of epicardial coronary artery thrombosis, show imaging data supporting the diagnosis of acute myocarditis; also, cases of fulminant myocarditis and fatal arrhythmias have been described. Even if a direct cardiotoxic localization SARS-CoV-2 into myocytes has never been demonstrated, some authors showed autopic findings (eg, lymphocyte infiltrates and macrophagic response) compatible with viral myocarditis. Moreover, in a retrospective study by Ruan et al evaluating factors associated with mortality in 150 COVID-19 subjects, patients who died showed higher levels of troponin, myoglobin, C-reactive protein, serum ferritin, and interleukin-6, suggesting a high inflammatory burden in COVID-19 with a possible rise in myocarditis-related cardiac events. For acute myocarditis, a combination of cardiac magnetic resonance (CMR) and myocardial biopsy is the reference diagnostic method, preceded by coronary angiography to rule out acute coronary syndromes. This is also valid for COVID-19 patients.

Accordingly, Inciardi et al presented a case of a 53-year COVID-19
A woman who developed acute myocarditis diagnosed, after exclusion of coronary disease and TTE findings consistent with acute myocarditis (increased wall thickness, diffuse echo-bright myocardial appearance and diffuse LV hypokinesis, with LVEF 40%), by CMR as increased wall thickness with diffuse biventricular hypokinesis and signs of marked biventricular myocardial interstitial edema by T2-mapping sequences and late gadolinium enhancement. However, in critical patients and in this reduced healthcare services emergency status, CMR and myocardial biopsy could not be promptly available and coronary angiography would put unstable patients at higher risks. Therefore, an echocardiographic study could be used as the first investigation tool to orient diagnosis with high-sensitive but less specific findings, that are listed in Table 2. Additionally, LV longitudinal strain proved to correlate with myocardial edema detected by CMR in patients with acute myocarditis and its bull’s eye representation shows the localization of myocardial damage, with GLS typically reducing from endocardial to epicardial layer (Figure 1).

### Table 1: Useful echocardiographic findings to aid early diagnosis of acute myocardial involvement in COVID-19 patients

| Suggested diagnosis | Echocardiographic findings |
|---------------------|---------------------------|
| Acute coronary syndromes | • New regional LV or RV wall-motion abnormalities  
• New functional mitral regurgitation |
| Acute heart failure | • Unknown LV dilation and dysfunction  
• High LV filling pressures (transmitral PWD or TDI)  
• IVC dilation and/or elevated systolic PAP |
| Cardiac tamponade | • Considerable pericardial effusion  
• Respiratory variation of transmitral PWD pattern  
• RV dilation with interventricular septum shift  
• Diastolic RV and/or right atrial collapse  
• Dilated and noncollapsible IVC |
| Pulmonary embolism or acute cor pulmonale | • RV dilation and dysfunction (McConnell’s sign)  
• Elevation of mean and systolic PAP  
• Meso-systolic notch with transpulmonary PWD  
• RV failure secondary to high PEEP |

Abbreviations: IVC = inferior vena cava; LV = left ventricle; PAP = pulmonary artery pressure; PEEP = positive end-expiratory pressures; PWD = pulsed wave Doppler; TDI = tissue Doppler imaging.

McConnell’s sign: depressed contractility of RV free wall compared to RV apex. Common finding in case of pulmonary embolism.

### Table 2: Possible echocardiographic characteristics of acute myocarditis

| Echocardiographic parameters | Typical findings |
|-------------------------------|------------------|
| LV dimensions                | Either normal or increased |
| LV septal thickness          | Either normal or increased (transient LV pseudohypertrophy) |
| LV systolic function         | • LV diffuse hypokinesis  
• Patchy LV dysfunction (not corresponding coronary flow distribution or ECG anomalies)  
• Normal LV EF  
• Reduced LV strain by STE (segmental localization with bull’s eye) |
| LV diastolic function        | Common LV diastolic dysfunction (↓ E/A, ↑ E/E’)) |
| Right ventricle              | Sometimes RV global systolic dysfunction with or without RV dilation |
| Pericardium                   | Pericardial effusion  
Brightness of myo-pericardium |

Abbreviations: EF = ejection fraction; LV = left ventricle; STE = speckle tracking echocardiography.

### 4 | ACUTE HEART FAILURE

In patients with COVID-19, cardiovascular involvement leading to cardiac dysfunction and failure is not uncommon, probably due to systemic inflammatory response, innate immune-related myocardial damage, or respiratory-induced hypoxemia during COVID-19 progression. This also affects patients without history of chronic HF, which could rapidly develop severe HF and die for sudden cardiac death after COVID-19 infection. In fact, the most likely mechanism of HF in these patients is consequent to lung
disease, leading to oxygen supply/demand imbalance, high pulmonary vascular resistance, and PH, eventually causing acute RV overload and failure.\textsuperscript{33}

Therefore, in patients hospitalized for COVID-19, LV and RV structure and function changes and cardiac filling pressures should be assessed. For this purpose, beyond basic echocardiographic parameters, additive tools could represent a strong support for clinicians: Firstly, lung ultrasound (LU) offers important information on acute hemodynamic changes in HF, through dynamic signs (ie, homogenous and diffuse B-lines and bilateral pleural effusion), allowing a quick diagnosis and monitoring of acute pulmonary edema.\textsuperscript{34} In this setting, it is important to differentiate between the typical LU signs of pulmonary edema and of COVID-19 leading to ARDS (ie, congestion, coalescent B-lines, the so-called "white lung," air bronchogram)\textsuperscript{35}. Even if clinical presentation are crucial for differential diagnosis, there are some notable differences between cardiogenic and COVID-19 B-lines: unlike the first, B-lines have a patchy and nongravity-related distribution, are commonly separated and coalescent, and present well-defined spared areas in COVID-19 pneumonia\textsuperscript{36}. However, sometimes these patients could show overlap patterns; thus, LU results should be taken cautiously.\textsuperscript{37}
In addition, offline speckle tracking analysis provides noninvasive early detection of myocardial damage in patients with HF, studying the deformation of all cardiac chambers, which revealed to have a correlation with LV filling pressures.\textsuperscript{38-41}

A comprehensive evaluation of these patients, including clinical, basic, and advanced ultrasonographic parameters, could be useful for an accurate prognostic assessment: In fact, it has been demonstrated that, in patients with acute HF, underlying pathologies, changes in renal function and TTE findings are associated with mortality.\textsuperscript{42} Moreover, a recent study by Li et al investigating in-hospital mortality in 120 patients with COVID-19 has shown RV dilatation and dysfunction in nonsurvivors and found global right ventricular longitudinal strain (RVLS) < 23% to be an independent predictor of mortality with multivariate analysis (AUC = 0.87, P < .001).\textsuperscript{43}

As regards treatment, ACC guidance for COVID19 advises the clinicians to be careful in using intravenous fluid therapy in patients with HF or volume overload conditions, since fluid administration for viral infection should be used cautiously and attentively monitored.\textsuperscript{44} Furthermore, the response to HF treatment should be continuously assessed since, in case of failing pharmacological therapy for HF, a timely transition to more aggressive treatment with extracorporeal membrane oxygenation (ECMO) or circulatory assistance for the study of septic shock, which could offer important information on cardiac loss of function due to sepsis. It has been shown that in these patients a certain grade of diastolic dysfunction could be detected by power and tissue Doppler imaging (TDI): The most used parameter is transmitral E/E’ ratio, with a lack of defined cut-off value; however, a higher proportion of diastolic dysfunction with values of E’ < 8-10 cm/s was found to be independently associated with higher risk of death\textsuperscript{46} (odds ratio, OR 7.7 of ICU mortality in a study by Mourad et al\textsuperscript{45}). Moreover, advanced echocardiography has shown good results for the evaluation of patients with septic shock: Orde et al demonstrated the superior value of STE over basic echocardiography in 60 patients with septic shock, detecting LV strain and RV strain impairment in 69% and 72% of patients, respectively, with only 33% patients having reduced LV ejection fraction (EF) and 32% having RV dysfunction based on conventional echocardiography (tricuspid annular plane systolic excursion, TDI s’ wave, RV fractional area change); moreover, they found RV-free wall strain to be moderately associated with 6-month mortality (OR 1.1, AUC 0.68).\textsuperscript{50} Afterward, Chang et al proposed a cutoff of GLS absolute value <13% as the best marker of ICU mortality in septic shock.\textsuperscript{51}

The use of echocardiography in this clinical setting could help clinicians in early recognizing myocardial damage due to COVID-derived sepsis.

6 | CRITICAL PATIENTS: FOCUS ON THE RIGHT VENTRICLE

According to common ARDS management,\textsuperscript{52} WHO indications emphasize treatment with mechanical ventilation with high PEEP and prone positioning for COVID-19 patients who finally develop ARDS.\textsuperscript{53} Nevertheless, the potential harmful effect of high PEEP,\textsuperscript{54} in means of end-inspiratory overdistension leading to lung injury and higher pulmonary vascular resistance, should not be overlooked\textsuperscript{55}; in fact, WHO recommends limiting this therapeutic strategy to moderate or severe ARDS and to responders.\textsuperscript{53} Owing to the close lung-heart interaction, this effect could also lead to acute cor pulmonale, causing RV systolic and diastolic overload.\textsuperscript{56} This is clearly shown by TTE as new RV dilation, end-systolic paradoxical septal movement, and reduced RV overall function\textsuperscript{57,58} and is characterized by poor prognosis due to circulatory failure.\textsuperscript{59,60} In the retrospective study by Zhou et al investigating the clinical course of 191 SARS-CoV-2 patients, 17% of patients required mechanical ventilation, 97% of whom died.\textsuperscript{45} Whether it was due to the end-stage disease or to ventilation-induced heart and/or lung complications is not known.

However, further evidence on this topic is timely needed in order improve the therapeutic management of COVID-19 patients.

Transesophageal echocardiography (TOE) has been widely used for monitoring ventilated patients in the last years. In fact, in these patients TTE is often challenging, due to the position of patients with lower mobility, and the poor acoustic window due to hyperinflated lungs. However, the development of new indices for the assessment of LV systolic/diastolic function and filling pressures by TDI, and of RV dimension and function, have led to reconsider the use of serial TTE for noninvasive monitoring of ventilated patients.\textsuperscript{61}

Thanks to the widespread use of echocardiography in ICU, RV dimension and function could be closely monitored in these patients.\textsuperscript{62,63} As Repessé et al suggested, a RV-driven adjustment of PEEP levels could help intensivists to find a balance between risks
and benefits of this therapeutic approach (ie, lung recruitment and overdistension),\textsuperscript{56} thus preventing early mortality for ventilation-induced RV failure. \textit{LU} could be an important ally also in this context.\textsuperscript{64} In addition, RV myocardial performance index (RV MPI), also known as “Tei index” determined on trans-tricuspid velocities by pulsed wave or tissue Doppler imaging, is a high-sensitive index for the diagnosis of RV dysfunction.\textsuperscript{65} It could be used for monitoring high-PEEP response in intubated patients, since it has shown to predict RV damage caused by mechanical ventilation\textsuperscript{64} and high PEEPs.\textsuperscript{67}

Moreover, it seems that severe COVID-19 infection could precipitate predisposition to acute venous thromboembolism, as shown in recent case reports,\textsuperscript{58,69} and highlighted by Dolhnikoff et al on autopic evidence,\textsuperscript{70} which could lead to further deterioration of patients’ clinical status. Beyond clinical suspicion, echocardiographic signs of RV overload (ie, pulmonary ejection acceleration time < 60 ms with a peak systolic tricuspid valve gradient < 60 mm Hg, or with depressed contractility of RV free wall compared to RV apex, the so-called McConnell’s sign) could suggest the diagnosis of acute PE with high positive predictive value.\textsuperscript{71} This should aid in providing early full anticoagulation therapy to these patients, avoiding long waiting times due to computed tomography (CT) scarce availability, and repeat CT scan with further radiation exposure.

Therefore, serially performing TTE in critical patients could represent a useful tool to guide airway management and to early recognize possible COVID-19 thromboembolic complications.

7 | THE CHOICE OF THE RIGHT DEVICE AND TECHNIQUE

Due to the need of balancing between risks of contagion for and benefits for patients, the common indications and modalities to perform echocardiography should be reconsidered in COVID-19 patients; therefore, the choices for the use of portable devices and transesophageal echocardiography should be tailored on the single patients depending on his clinical status and cardiovascular conditions.

Portable machines have the advantage to be easier to clean and to cover than common echocardiographic machines and could be preferred for a basic assessment of biventricular function, valvular disease, and pericardial effusion.\textsuperscript{12} However, in patients with suspected or known cardiac impairment or in uncertain clinical cases, the quality of the TTE evaluation could be sacrificed using portable echocardiographers. As an alternative, we propose the use of a dedicated echocardiographic machine in COVID units which should also be sanitized after use, thus combining safety and effectiveness. In addition, for difficult cases or severe cardiac dysfunction, we suggest performing a comprehensive image acquisition with offline measurement of complex and advanced parameters in a safe environment and at clinician time discretion, in order to obtain a complete echocardiographic examination reducing the time of exposure to SARS-CoV-2.

As regards TOE, there are several clinical settings in which this would provide more accurate information than TTE, such as a better anatomic insight into valvular heart disease, exclusion of vegetations on valvular structures or central venous catheters, or intracardiac shunts, assessment of RV function in ventilated patients, poor quality of bedside TTE images.

However, TOE might be stressful to COVID-19 patients and, as suggested by EACVI consensus document, it should be avoided in most patients with ongoing COVID-19. Moreover, the risk of contamination of healthcare workers and surfaces is very high during the procedure due to droplets and aerosols containing virus, therefore, in each case of performing TOE to suspected or known COVID-19 patients, wearing advanced personal protective equipment (filtering face piece particulate class-3 (FFP3) respirator, gown, gloves, and eye protection) is compulsory, and a dedicated transoesophageal probe in COVID units would be required. All this given, we suggest to carefully consider each indication for TOE and procrastinate them if inappropriate.

Usefulness of echocardiography for ECMO monitoring is a widely discussed topic in the recent times. In fact, TTE or TOE have a pivotal role not only for the evaluation of biventricular function pre-, during, and post-ECMO and a serial assessment of patient’s loading conditions, which could help therapeutic management and decision-making, but also for anatomic assessment of the correct positioning of the device, and the presence of complications such as intracardiac thrombotic formations. The latter application could be of great importance in COVID-19 patients for their known pro-thrombotic state, as shown by Schmiady et al in a case-report describing a young patient with severe COVID-19 respiratory consequences requiring veno-venous ECMO assistance, who developed multiple thrombi, including in inferior vena cava (IVC) and right atrium, and underwent TOE-guided percutaneous thrombectomy. TOE would possibly offer most reliable information for this purpose, but the previous discussed concerns should be considered and the use of TTE should be preferred when applicable.\textsuperscript{72}

8 | CONCLUSIONS

Echocardiography is a precious tool in the hands of an expert operator to improve diagnostic procedures and therapeutic management of patients with COVID-19, aiding clinicians in early recognizing subtle cardiac damage and providing adequate treatment for SARS-CoV-2-infected subjects. The use of TTE could change the diagnostic workup of acute coronary syndromes, myocarditis, acute left or right ventricular failure, and secondary myocardial damage due to sepsis or mechanical ventilation, allowing noninvasive assessment and monitoring.

However, the prevention of COVID-19 spread should not be forgotten; therefore, it is crucial to bear in mind the mandatory use of personal protective equipment (with the use of FFP3 respirator, gown, gloves, and eye protection to face COVID-19 ill),\textsuperscript{12} and the safety recommendations to perform echocardiography at the time...
of COVID outbreak. Figure 3 resumes the parameters to assess for different suitable applications of echocardiography in COVID-19 patients.

CONFLICT OF INTEREST
No disclosures.

ORCID
Matteo Cameli https://orcid.org/0000-0003-3872-8964
Maria Concetta Pastore https://orcid.org/0000-0002-7223-141X

REFERENCES
1. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 3 May 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200503-covid-19-sitrep-104.pdf?sfvrsn=53328f46_2. Accessed May 3, 2020.
2. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) - China, 2020. China CDC Weekly. 2020;2(8):113–122.
3. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf. Accessed February 24, 2020.
4. Tan ZC, Fu LH, Wang DD, Hong K. Cardiac manifestations of patients with COVID-19 pneumonia and related treatment recommendations. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48:E005.
5. Zheng YY, Ma YT, Zhang JY, Xie Y. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259.
6. He XW, Lai JS, Cheng J, et al. Impact of complicated myocardial injury on the clinical outcome of severe or critically ill COVID-19 patients. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48:E011.
7. Yao XH, Li TY, He ZC, et al. A pathological report of three COVID-19 cases by minimally invasive autopsies. Zhonghua Bing Li Xue Za Zhi. 2020;49:E009.
8. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5:e200950. https://doi.org/10.1001/jamacardio.2020.0950. [Epub ahead of print].
9. Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5:e201017. https://doi.org/10.1001/jamacardio.2020.1017. [Epub ahead of print].
10. Popescu BA, Andrade MJ, Badano LP, et al. European Association of Echocardiography recommendations for training, competence, and quality improvement in echocardiography. Eur J Echocardiogr. 2019;10(8):892–905.
11. Kirkpatrick JW, Mitchell C, Taub C, Kort S, Hung J, Swaminathan M. ASE statement on protection of patients and echocardiography service providers during the 2019 novel coronavirus outbreak. J Am Coll Cardiol. 2020;75(24):3078–3084.
12. Skulstad H, Cosyns B, Popescu BA, et al. COVID-19 pandemic and cardiac imaging: EACVI recommendations on precautions, indications, prioritization, and protection for patients and healthcare personnel. Eur Heart J Cardiovasc Imaging. 2020;21(6):592–598.
13. Maddox TM, Webster SE, Bodurkturk B, ACC Science and Quality Committee. COVID-19 Clinical Guidance for the Cardiovascular Care Team. https://www.acc.org/-/media/Non-Clinical/Files-PDFs-
14. Valente S, Anselmi F, Cameli M. Acute coronary syndromes during COVID-19. *Eur Heart J*. 2020;41(22):2047–2049. http://dx.doi.org/10.1093/eurheartj/ehaa457. [Epub ahead of print].

15. Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): evidence from a meta-analysis. *Prog Cardiovasc Dis*. 2020. https://doi.org/10.1016/j.pcad.2020.03.001. [Epub ahead of print].

16. Chen C, Chen C, Yan JT, Zhou N, Zhao JP, Wang DW. Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19. *Zhonghua Xin Xue Guan Bing Za Zhi*. 2020;48:E008.

17. Stefanini GG, Montorfano M, Trabattoni D, et al. ST-Elevation myocardial infarction in patients with COVID-19: clinical and angiographic outcomes. *Circulation*. 2020;141(25):2113–2116.

18. Peng F, Tu L, Yang Y, et al. Management and treatment of COVID-19: the chinese experience. *Can J Cardiol*. 2020;36(6):915–930.

19. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China/J/OL. JAMA. 2020;323(11):1061.

20. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. *Front Med*. 2020;14(2):185–192.

21. Hendren NS, Drazner MH, Bozkurt B, Cooper LT Jr. Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome. *Circulation*. 2020;141(23):1903–1914.

22. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). *JAMA Cardiol*. 2020. https://doi.org/10.1001/jamacardio.2020.1096. [Epub ahead of print].

23. Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. *Eur Heart J*. 2020;ehaa190. https://doi.org/10.1093/eurheartj/ehaa190. [Epub ahead of print].

24. Zeng JH, Liu YX, Yuan J, et al. First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. *Infection*. 2020;1–5. https://doi.org/10.1007/s15010-020-01424-5. [Epub ahead of print].

25. Sala S, Perretto G, Gramena M, et al. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. *Eur Heart J*. 2020;41(19):1861–1862.

26. Tavazzi G, Pellegrini C, Maurelli M, et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. *Eur J Heart Fail*. 2020;22(5):911–915.

27. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med*. 2020;8(4):420–422.

28. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med*. 2020;46(5):846–848.

29. Pollack A, Kontorovich AR, Fuster V, et al. Viral myocarditis—diagnosis, treatment options and current controversies. *Nat Rev Cardiol*. 2015;12(11):670–680.

30. Sinagra G, Anzini M, Pereira NL, et al. Myocarditis in clinical practice. *Mayo Clin Proc*. 2016;91(9):1256–1266.

31. Løgstrup BB, Nielsen JM, Kim WY, Poulsen SH. Myocardial oedema in acute myocarditis detected by echocardiographic 2D myocardial deformation analysis. *Eur Heart J Cardiovasc Imaging*. 2016;17(9):1018–1026.

32. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system: a review. *JAMA Cardiol*. 2020. https://doi.org/10.1001/jamacardio.2020.1286. [Epub ahead of print].

33. Clerkin KJ, Fried JA, Raikhelkar J, et al. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease. *Circulation*. 2020;141(20):1648–1655.

34. Gargani L. Ultrasound of the lungs: more than a room with a view. *Heart Fail Clin*. 2019;15(2):297–303.

35. Vetrugno L, Bove T, Orso D, et al. Our Italian experience using lung ultrasound for identification, grading and serial follow-up of severity of lung involvement for management of patients with COVID-19. *Echocardiography*. 2020;37(4):625–627.

36. Gargani L, Soliman-Abouramie H, Volpicelli G, Corradi F, Pastore MC, Cameli M. Why, when, and how to use lung ultrasound during the COVID-19 pandemic: enthusiasm and caution. *Eur Heart J Cardiovasc Imaging*. 2020. http://dx.doi.org/10.1093/ehjci/jeaa163. [Epub ahead of print].

37. Vetrugno L, Bove T, Orso D, et al. Lung ultrasound and the COVID-19 “Pattern”: not all that glitters today is gold tomorrow. *J Ultrasound Med*. 2020. https://doi.org/10.1002/jum.15327. [Epub ahead of print].

38. Pastore MC, Mandoli GE, Abouramie HS, et al. Working Group of Echocardiography of the Italian Society of Cardiology. Basic and advanced echocardiography in advanced heart failure: an overview. *Heart Fail Rev*. 2019. https://doi.org/10.1007/s10741-019-09865-3. [Epub ahead of print].

39. Cameli M, Pastore MC, Mandoli GE, et al. Prognosis and risk stratification of patients with advanced heart failure (from PROBE). *Am J Cardiol*. 2019;124(1):55–62.

40. Cameli M, Pastore MC, Henein MY, et al. (2019) The left atrium and the right ventricle: two supporting chambers to the failing left ventricle. *Heart Fail Rev*. 2019;24(5):661–669.

41. Badano LP, Kolas TJ, Muraru D, et al. Standardization of left atrial, right ventricular, and right atrial deformation imaging using two-dimensional speckle tracking echocardiography: a consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. *Eur Heart J Cardiovasc Imaging*. 2018;19(6):591–600.

42. Cameli M, Pastore MC, De Carli G, et al. ACUTE HF score, a multiparametric prognostic tool for acute heart failure: a real-life study. *Int J Cardiol*. 2019;296:103–108.

43. Li Y, Li H, Zhu S, et al. Prognostic Value of Right Ventricular Longitudinal Strain in Patients with COVID-19. *J Am Coll Cardiol Img*. 2020. https://doi.org/10.1016/j.jcmg.2020.04.014. [Epub ahead of print].

44. Franchi F, Vetrugno L, Scelletta S. Echocardiography to guide fluid therapy in critically ill patients: check the heart and take a quick look at the lungs. *J Thorac Dis*. 2017;9(3):477–481.

45. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;395(10229):1054–1062.

46. WHO Interim guidance 13th March 2020. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. WHO/2019-nCoV/clinical/2020.4. Accessed March 13, 2020.

47. Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. *JAMA*. 2001;286:1754–2175.

48. Gonzalez C, Begot E, Dalmay F, et al. (2016) Prognostic impact of left ventricular diastolic function in patients with septic shock. *Ann Intensive Care*. 2016;6(1):36.

49. Mourad M, Chow-Chine L, Faucher M, et al. Early diastolic dysfunction is associated with intensive care unit mortality in cancer patients presenting with septic shock. *Br J Anaesth*. 2014;112(1):102–109.

50. Orde SR, Pulido JN, Masaki M, et al. Outcome prediction in sepsis: speckle tracking echocardiography based assessment of myocardial function. *Crit Care*. 2014;18:R149.
51. Chang W-T, Lee W-H, Lee W-T, et al. Left ventricular global longitudinal strain is independently associated with mortality in septic shock patients. *Intensive Care Med*. 2015;41:1791–1799.

52. Writing Group for the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial Investigators, Cavalcanti AB, Suzumura ÉA, et al. Effect of lung recruitment and titrated positive end-expiratory pressure (PEEP) vs low PEEP on mortality in patients with acute respiratory distress syndrome: a randomized clinical trial. *JAMA*. 2017;318:1335–1345.

53. World Health Organization. *Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: Interim guidance*. World Health Organization; 2020. https://apps.who.int/iris/handle/10665/330893. Accessed January 28, 2020.

54. Gage A, Higgins A, Lee R, Panhwar MS, Kalra A. Reacquainting Cardiology with Mechanical Ventilation in Response to the COVID-19 Pandemic. *JACC Case Rep*. 2020. https://doi.org/10.1016/j.jaccr.2020.03.007. [Epub ahead of print].

55. Goligher EC, Kavanagh BP, Rubenfeld GD, et al. Oxygenation response to positive end-expiratory pressure predicts mortality in acute respiratory distress syndrome. A secondary analysis of the LOVS and ExPress trials. *Am J Respir Crit Care Med*. 2014;190:70–76.

56. Repessé X, Charron C, Vieillard-Baron A. Acute cor pulmonale in ARDS: rationale for protecting the right ventricle. *Chest*. 2015;147(1):259–265.

57. Jardín F, Dubourg O, Bourdarias JP. Echocardiographic pattern of acute cor pulmonale. *Chest*. 1997;111(1):209–217.

58. Boissier F, Katsahian S, Razazi K, et al. Prevalence and prognosis of cor pulmonale during protective ventilation for acute respiratory distress syndrome. *Intensive Care Med*. 2013;39(10):1725–1733.

59. Franchi F, Faltoni A, Cameli M, et al. Influence of positive end-expiratory pressure on myocardial strain assessed by speckle tracking echocardiography in mechanically ventilated patients. *Biomed Res Int*. 2013;2013:918548.

60. Lhéritier G, Legras A, Caille A, et al. Prevalence and prognostic value of acute cor pulmonale and patent foramen ovale in ventilated patients with early acute respiratory distress syndrome: a multicenter study. *Intensive Care Med*. 2013;39(10):1734–1742.

61. Vieillard-Baron A, Prin S, Chergui K, Dubourg O, Jardín F. Echo-Doppler demonstration of acute cor pulmonale at the bedside in the medical intensive care unit. *Am J Respir Crit Care Med*. 2002;166(10):1310–1319.

62. Salem R, Vallee F, Rusca M, Mebazaa A. Hemodynamic monitoring by echocardiography in the ICU: the role of the new echo techniques. *Curr Opin Crit Care*. 2008;14(5):561–568.

63. Pastore MC, De Carli G, Mandoli GE, et al. The prognostic role of speckle tracking echocardiography in clinical practice: evidence and reference values from the literature. *Heart Fail Rev*. 2020. https://doi.org/10.1007/s10741-020-09945-9. [Epub ahead of print].

64. Mojoli F, Bouhemad B, Mongodi S, Lichtenstein D. Lung Ultrasound for Critically Ill Patients. *Am J Respir Crit Care Med*. 2019;199(6):701–714.

65. Miller D, Farah MG, Liner A, et al. The relation between quantitative right ventricular ejection fraction and in dices of tricuspid annular motion and myocardial performance index. *J Am Soc Echocardiogr*. 2004;17:443–447.

66. Cherpanath TGV, Simonis FD, Bouma BJ, et al. Myocardial function during low versus intermediate tidal volume ventilation in patients without acute respiratory distress syndrome. *Anesthesiology*. 2020;132(5):1102–1113.

67. Geroth C, Wagner G, Pelosi P, Luecke T. Respiratory and haemodynamic changes during decremental open lung positive end-expiratory pressure titration in patients with acute respiratory distress syndrome. *Crit Care*. 2009;13(2):R59.

68. Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? *Eur Heart J*. 2020;41(19):1858.

69. Xie Y, Wang X, Yang P, Zhang S. COVID-19 complicated by acute pulmonary embolism. *Radiology*. 2020;22(2):e200067.

70. Dolnikoff M, Duarte-Neto AN, de Almeida Monteiro RA, et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. *J Thromb Haemost*. 2020;18(6):1517–1519.

71. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). *Eur Heart J*. 2020;41(4):545–603.

72. Schmiady MO, Sromicki J, Kucher N, Ouda A. Successful percutaneous thrombectomy in a patient with COVID-19 pneumonia and acute pulmonary embolism supported by extracorporeal membrane oxygenation. *Eur Heart J*. 2020;ehaa403. https://doi.org/10.1093/eurheartj/ehaa403

---

**How to cite this article:** Cameli M, Pastore MC, Soliman Aboumarie H, et al. Usefulness of echocardiography to detect cardiac involvement in COVID-19 patients. *Echocardiography*. 2020;37:1278–1286. [https://doi.org/10.1111/echo.14779](https://doi.org/10.1111/echo.14779)